GlassScriptPhysician profile
Amber M Mack
NPI 1811209828
$3,561.57
in general payments reported to CMS, 2019-2025
40 companies · $783 in 2025
The $783 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $137 · 2021: $347 · 2022: $676 · 2023: $614 · 2024: $634 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.18 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.02 | 2019-2025 | |
| Astellas Pharma US INC | $430.25 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $330.52 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $312.32 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $192.16 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $163.94 | 2019-2022 | |
| Agile Therapeutics, INC. | $150.28 | 2021-2024 | Twirla |
| Pfizer INC. | $144.65 | 2019-2024 | |
| Shield Therapeutics INC | $119.94 | 2022-2025 | Accrufer |
| Coopersurgical, INC. | $107.80 | 2023-2025 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Exeltis, USA INC. | $105.13 | 2020-2024 | Slynd |
| Exact Sciences Corporation | $88.58 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $74.84 | 2022-2024 | |
| Hologic Sales and Service, LLC | $72.84 | 2020-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Myovant Sciences INC. | $62.86 | 2021-2022 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.